Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study

BACKGROUND: Despite the availability of new direct-acting antiviral (DAA) regimens, changes in DAA reimbursement criteria, and a public health focus on hepatitis C virus (HCV) elimination, it remains unclear if public and private insurers have increased access to these therapies over time. We evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Gowda, Charitha, Lott, Stephen, Grigorian, Matthew, Carbonari, Dena M, Saine, M Elle, Trooskin, Stacey, Roy, Jason A, Kostman, Jay R, Urick, Paul, Lo Re, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016397/
https://www.ncbi.nlm.nih.gov/pubmed/29977955
http://dx.doi.org/10.1093/ofid/ofy076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016397/
https://www.ncbi.nlm.nih.gov/pubmed/29977955
http://dx.doi.org/10.1093/ofid/ofy076

Ejemplares similares